CGEM - Cullinan Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$31.25
DETAILS
HIGH:
$37.00
LOW:
$28.00
MEDIAN:
$30.00
CONSENSUS:
$31.25
UPSIDE:
90.43%
About Cullinan Therapeutics, Inc. (https://cullinantherapeutics.com)
Cullinan Therapeutics, Inc. operates as a biopharmaceutical firm actively advancing its therapeutic candidates through clinical trials. This company is focused on developing innovative treatments primarily for cancer, including those that leverage the immune system (immuno-oncology). Its current roster of investigational drugs comprises CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. Patrick A. Baeuerle founded the organization on September 15, 2016, and it is presently headquartered in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Nadim Ahmed | President, Chief Executive Officer & Director | 1968 | $1,168,266 USD |
| Jeffrey Jones | Chief Medical Officer | 1971 | $801,783 USD |
| Mary Kay Fenton | Chief Financial Officer | 1964 | $768,257 USD |
| Patrick A. Baeuerle | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | 1958 | $763,734 USD |
| Corinne Savill | Chief Business Officer | 1959 | – |
| Jacquelyn L. Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | 1978 | – |
| Jennifer Michaelson | Chief Scientific Officer | 1967 | – |
| Nicholas Smith | Head of Investor Relations | – | – |
| Rose Weldon | Senior Vice President of Corporate Affairs | – | – |
| Steve Andre | Chief Human Resources Officer | – | – |